• Iqbal Hanash Dhefer Department of Chemistry, The University of Al-Mustansiriya, College of Science, Baghdad, Iraq
  • Salma Abdul Rudha Abbas Department of Chemistry, The University of Al-Mustansiriya, College of Science, Baghdad, Iraq
  • Najwa Sh Ahmed Department of Biotechnology, Biotechnology Research, Molecular, and Biotechnology Laboratory, AL-Nahrain University, Baghdad, Iraq




Aromatase activity, Single-nucleotide polymorphism, rs2236722, Active acromegaly


Objective: The objective of the present work was to investigate the association between aromatase enzyme activity and polymorphisms, rs2236722, in exon 2 of cytochrome P450 (CYP), superfamily19, polypeptide 1 (CYP19A1gene) in patients with active acromegaly.

Methods: A total of 120 males and females (age 20-60 years) were enrolled in this study, 60 patients with active acromegaly who have attended the National Diabetes Centre and and Specialist Center for endocrinology and diabetes, Baghdad, from December 2015 to June 2016 and 60 healthy individuals with matches as a control group. From the whole blood, genomic DNA was extracted to perform genotyping analysis and single-nucleotide polymorphism, rs2236722, in the CYP19A1 gene using multiplex polymerase chain reaction technique, and serum aromatase levels were determined using a solid-phase enzyme-linked immunosorbent assay based on sandwich method.

Results: The results show that the aromatase activity levels of patients were a highly significant decrease when contrasted with healthy control groups in both sexes (p≤0.01), and there were summarized positive results of an allele in single-nucleotide polymorphism, rs2236722, were highly significant in TT allele when contrasted with healthy control groups. While revealed that there was non-significant difference in TC allele when contrasted with healthy control groups (p>0.01).

Conclusion: we conclude that there was associated between CYP19A1 gene polymorphism (rs2236722) with aromatase activity and related to acromegaly patients.


Download data is not yet available.


Fougner SL, Bollerslev J, Svartberg J, Øksnes M, Cooper J, Carlsen SM. Preoperative octreotide treatment of acromegaly: Long-term results of a randomised controlled trial. Eur J Endocrinol 2014;171(2):229-35.

Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99(11):3933-51.

Koleva DI, Orbetzova MM, Atanassova PK. Adipose tissue hormones and appetite and body weight regulators in insulin resistance. Folia Med (Plovdiv) 2013;55(1):25-32.

Nagar S, Saha A. Qsar moeling and pharmacophore mapping of isoflavone derivatives for aromatase inhibitory activity. Int J Pharm Pharm Sci 2010;2 Suppl 3:126-31.

Selek A, Cetinarslan B, Gurbuz Y, Tarkun I, Canturk Z, Cabuk B. Aromatase enzyme expression in acromegaly and its possible relationship with disease prognosis. Endocrine 2015;49:250-7.

Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137(12):5739-42.

Reed MJ, Purohit A. Aromatase regulation and breast cancer. Clin Endocrinol (Oxf) 2001;54(5):563-71.

Boone SD, Baumgartner KB, Baumgartner RN, Connor AE, Pinkston CM, Rai SN, et al. Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: The breast cancer health disparities study. Cancer Causes Control 2014;25(11):1461-71.

Lephart ED. Modulation of aromatase by phytoestrogens. Hindawi Publ Corp Enzyme Res 2015;2015:11.

Di Nardo G, Gilardi G. Human aromatase: Perspectives in biochemistry and biotechnology. Biotechnol Appl Biochem 2013;60(1):92-101.

Olin JL, St Pierre M. Aromatase inhibitors in breast cancer prevention. Ann Pharmacother 2014;48(12):1605-10.

Chen C, Sakoda LC, Doherty JA, Loomis MM, Fish S, Ray RM, et al. Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2008;17(12):3457-66.

Fasching PA, Loehberg CR, Strissel PL, Lux MP, Bani MR, Schrauder M, et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat 2008;112(1):89-98.

Lin L, Ercan O, Raza J, Burren CP, Creighton SM, Auchus RJ, et al. Variable phenotypes associated with aromatase (CYP19) insufficiency in humans. J Clin Endocrinol Metab 2007;92(3):982-90.

Wang L, Lu X, Wang D, Qu W, Li W, Xu X. CYP19 gene variant confers susceptibility to endometriosis-associated infertility in Chinese women. Exp Mol Med 2014;46(6):e103.

Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, et al. Genetic variants of CYP19 (aromatase) and breast

cancer risk. Oncogene 2000;19(10):1329-33.

Hur SE, Lee S, Lee JY, Moon HS, Kim HL, Chung HW. Polymorphisms and haplotypes of the gene encoding the estrogen-metabolizing CYP19 gene in Korean women: No association with advanced-stage endometriosis. J Hum Genet 2007;52(9):703-11.

Kado N, Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, et al. Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Hum Reprod 2002;17(4):897-902.

Trabert B, Schwartz SM, Peters U, De Roos AJ, Chen C, Scholes D, et al. Genetic variation in the sex hormone metabolic pathway and endometriosis risk: An evaluation of candidate genes. Fertil Steril 2011;96(6):1401-6.e3.

Hirose K, Matsuo K, Toyama T, Iwata H, Hamajima N, Tajima K. The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. Cancer Epidemiol Biomarkers Prev 2004;13(8):1407-11.

Huang CS, Kuo SH, Lien HC, Yang SY, You SL, Shen CY, et al. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers. Oncologist 2008;13(7):751-60.

Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Yamamura J, Irahara N, et al. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer 2003;39(17):2531-7.

Hamaguchi M, Nishio M, Toyama T, Sugiura H, Kondo N, Fujii Y, et al. Possible difference in frequencies of genetic polymorphisms of estrogen receptor α, estrogen metabolism, and P53 genes between estrogen receptor-positive and negative breast cancers. Jpn J Clin Oncol 2008;38(11):734-42.

Leporati P, Fonte R, de Martinis L, Zambelli A, Magri F, Pavesi L, et al. A male patient with acromegaly and breast cancer: Treating acromegaly to control tumor progression. BMC Cancer 2015;15:397.

Surekha D, Sailaja K, Rao DN, Padma T, Raghunadharao D, Vishnupriya S. Association of CYP19 polymorphisms with breast cancer risk: A case-control study. J Nat Sci Biol Med 2014;5(2):250-4.

Belgorosky A, Guercio G, Pepe C, Saraco N, Rivarola MA. Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence. Horm Res 2009;72(6):321-30.

Paul CB, Sudaniradoss C. Aromatase inhibiters-types and advantages. Int J Pharm Pharm Sci 2016;8(8):1-7.



How to Cite

Dhefer, I. H., S. A. R. Abbas, and N. S. Ahmed. “POLYMORPHISM OF CYTOCHROME P450, SUPERFAMILY19, POLYPEPTIDE 1 GENE AND RELATED TO AROMATASE ENZYME ACTIVITY IN ACROMEGALY IRAQI PATIENTS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 6, June 2017, pp. 228-32, doi:10.22159/ajpcr.2017.v10i6.17886.



Original Article(s)